Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.67 +3.7% SGZ 0.040 −11.1% GRSL 0.310 −3.1%
Regulatory Routine +

MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling

US Rescheduling Confirmed, But Canadian Revenue Headwinds Loom

By The Northwire Desk — AI Analysis Apr 27, 2026 · 08:30 LABS · 0.065 MEDIPHARM LABS CORP. J
Executive Summary
  • The U.S. Department of Justice and DEA final order rescheduling cannabis from Schedule I to Schedule III took effect on April 22, 2026.
  • MediPharm Labs confirms operational readiness with existing FDA site registration and Health Canada Drug Establishment License (DEL).
  • Company highlights track record supplying over 10 active clinical trials including NIH-funded studies.
  • Regulatory shift expected to remove "Schedule I trafficking" restrictions for institutional investors, potentially increasing capital inflow.
  • This news validates the December 2025 Executive Order announcement and confirms the implementation timeline.
Material Impact
  • The regulatory change is material in principle but largely priced in following the December 2025 announcement.
  • Confirmation of effective date removes uncertainty regarding Section 280E tax implications for U.S. research partners.
  • No new revenue contracts or specific U.S. sales figures disclosed in this release, limiting immediate financial impact.
  • The news reinforces the company's pharmaceutical positioning but does not alter the fundamental risk profile regarding domestic Canadian revenue cuts.
  • Market reaction has been muted (price stagnation), suggesting investors view this as expected execution rather than a new catalyst.
LABS · Price
Company Overview
  • MediPharm Labs operates across four verticals: International Medical Cannabis, Canadian Medical Cannabis, Pharmaceutical/B2B, and Adult-Use/Wellness.
  • Flagship Project: GMP-certified production facilities in Canada (Napanee) with EU-GMP compliance and FDA-inspected status.
  • Key Assets: Two owned production facilities valued at >$15M; Health Canada Drug Establishment License (DEL).
  • Global Footprint: Supplies medical cannabis to Germany, UK, Australia, France, Brazil, and New Zealand.
  • Clinical Focus: Active participation in over 10 U.S. clinical trials including NIH-funded studies.
Read the original news release →

More from MEDIPHARM LABS CORP. J

May 28, 2026 · 08:00

MediPharm Labs Turns EBITDA Positive Amidst Revenue Contraction and Governance Shifts

Regulatory May 13, 2026 · 07:30

MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.

Earnings Mar 30, 2026 · 07:45

MediPharm Posts Margin Recovery and Steady International Growth, Yet Profitability Remains Elusive

Earnings Mar 25, 2026 · 19:05

MediPharm Delivers Margin Recovery and Near-Breakeven EBITDA as International Sales Offset Domestic Stagnation

Earnings Jan 19, 2026 · 08:00

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Management Jan 13, 2026 · 18:47

Medipharm Labs signs Costa Rica supply agreement

M&A / Property